Skip to main content
G

GUANGDONG VTR BIO-TECH CO., LTD. — Investor Relations & Filings

Ticker · 300381 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,040 across all filing types
Latest filing 2026-04-24 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300381

About GUANGDONG VTR BIO-TECH CO., LTD.

https://www.yiduoli.com

GUANGDONG VTR BIO-TECH CO., LTD. specializes in the research, development, and manufacturing of biological enzyme preparations and steroid hormone products. The company’s portfolio includes a wide range of feed enzymes, food enzymes, and textile enzymes, as well as functional feed additives and pharmaceutical intermediates. Its operations focus on providing high-performance biological solutions for animal nutrition, food processing, and pharmaceutical manufacturing. Utilizing advanced fermentation and purification technologies, the company produces key products such as phytase, xylanase, and various steroid hormone APIs. The organization prioritizes technical innovation to improve production efficiency and support sustainable industrial practices. Its products are distributed to a global market, catering to diverse technical requirements in biological and chemical applications.

Recent filings

Filing Released Lang Actions
关于作废2025年限制性股票激励计划部分已授予尚未归属的限制性股票的公告
Regulatory Filings Classification · 1% confidence The document is an official corporate announcement by Guangdong Wendoleri Biotech regarding the cancellation of part of its 2025 restricted stock incentive plan. It does not present full financial results (so not an Annual Report, Interim Report or Earnings Release), nor is it a transcript, voting results, delisting notice, dividend notice, or management change. It specifically addresses adjustments to an equity incentive plan, which falls outside the other narrowly defined categories (e.g., share issues, buybacks, proxy materials). Accordingly, it is best classified as a general regulatory announcement under the fallback category "Regulatory Filings (RNS)."
2026-04-24 Chinese
第八届董事会第十八次会议决议公告
Regulatory Filings Classification · 0% confidence The document is an announcement of the board of directors’ meeting resolutions (“第八届董事会第十八次会议决议公告”), listing vote outcomes on various proposals (annual report, profit distribution, remuneration, audit appointments, fund usage, etc.). It is not the full annual or interim report itself, nor an earnings release, nor a proxy statement, nor a voting results announcement at a shareholder meeting. It also does not announce changes in board composition. There is no specific fitting category for “board resolutions” other than the general fallback “Regulatory Filings”. Therefore it should be classified as an RNS.
2026-04-24 Chinese
非经营性资金占用及其他关联资金往来的专项说明
Audit Report / Information Classification · 1% confidence The document is a standalone special-purpose explanation of the company’s non-operating fund occupancy and related party transactions for the 2025 year, prepared by Grant Thornton and signed by auditors. It references the audit work done for the full financial statements and provides a detailed schedule of related party fund movements, which is beyond a simple announcement and is a form of audit-related disclosure. This aligns with the definition of AR (Audit Report/Information) as a standalone audit‐related report distinct from the full annual report.
2026-04-24 Chinese
2025年度董事会工作报告
Management Reports Classification · 1% confidence The document is the “2025年度董事会工作报告” (Board of Directors Work Report) of Guangdong Yiduo Li Biotech Co., Ltd. It provides a detailed review of the company’s operations, business segments, governance, committee activities, and future plans. This is not the full audited annual report (10-K) nor a brief announcement; it is the management’s in‐depth discussion of performance, strategy, and outlook – fitting the definition of a Management Report (MDA).
2026-04-24 Chinese
2025年年度审计报告
Audit Report / Information Classification · 1% confidence The document is a standalone audit report (“审计报告”) by Grant Thornton to the shareholders of 广东溢多利生物科技股份有限公司, including audit opinion, key audit matters, auditor responsibilities, and full financial statements (balance sheet, income statement, cash flow, notes). It is not an Annual Report or mere announcement but the actual audit report itself. This matches the definition for Audit Report / Information (Code: AR).
2026-04-24 Chinese
2025年年度报告
Annual Report Classification · 1% confidence The document is the '2025 Annual Report' for '广东溢多利生物科技股份有限公司' (Guangdong VTR Bio-Tech Co., Ltd.). It contains comprehensive financial statements, management discussion and analysis (MDA), governance information, and auditor details for the fiscal year 2025. It is clearly a full annual report rather than an announcement or summary, fitting the definition of a 10-K (Annual Report). FY 2025
2026-04-24 Chinese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.